亿德体育

Be the most trusted biotech company

2024-05-24

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
2024-05-22

The Supplemental Applications of HANDAYUAN(adalimumab injection) for the New Indications Approved by the NMPA
2024-05-21

Henlius to Release Latest Clinical Data of HLX22 at 2024 ESMO GI
2024-05-16

Henlius to Showcase at BIO 2024
2024-05-15

First Patient Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2024-05-14

Henlius lasofoxifene HLX78 IND Approved by NMPA
2024-05-10

Henlius Holds its first Scientific Advisory Board Meeting of 2024
2024-05-06

Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA
2024-04-29

Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products

var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"}); 亿德体育|亿德体育官网 - 登录入口米乐m6 | m6米乐米乐m6 - 官网登录米乐m6 - 米乐m6官网米乐m6 - 米乐m6官网 - APP下载